Thursday, July 28, 2016

Phase III tau drug fails to meet endpoints but shows silver lining as monotherapy

Phase III tau drug fails to meet endpoints but shows silver lining as monotherapy:

Dementia Big
At AAIC2016, researchers from TauRx Therapeutics Ltd presented results from a phase III clinical trial of the drug leuco-methylthioninium-bis(hydromethanesulfonate) or LMTM in people with mild-to-moderate Alzheimer’s disease.


http://ift.tt/2acdoMz
Posted by at
Labels: , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)